` IMM (ImmuPharma PLC) vs FTSE All Share Index Comparison - Alpha Spread

IMM
vs
F
FTSE All Share Index

Over the past 12 months, IMM has significantly outperformed FTSE All Share Index, delivering a return of +413% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
IMM vs FTSE All Share Index

Loading
IMM
FTSE All Share Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
IMM vs FTSE All Share Index

Loading
IMM
FTSE All Share Index
Difference
www.alphaspread.com

Performance By Year
IMM vs FTSE All Share Index

Loading
IMM
FTSE All Share Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
ImmuPharma PLC vs Peers

FTSE All Share Index
IMM
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

ImmuPharma PLC
Glance View

Market Cap
30m GBX
Industry
Pharmaceuticals

ImmuPharma Plc engages in the research, development, and commercialization of pharmaceutical products. The firm is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The firm has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The firm's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The firm's research operations are in France.

IMM Intrinsic Value
Not Available
Back to Top